Ultragenyx shares fall 47% after GTX-102 misses late-stage goal
Ultragenyx’s stock sank 47% after its rare-disease drug candidate GTX-102 failed to meet its main goal in a late-stage trial, triggering a flurry of downgrades. Some analysts still cite pipeline potential.
By Mackenzie TatananniUltragenyx Pharmaceutical stock was hit with a flurry of downgrades after the biotech's rare-disease drug candidate, GTX-102, failed to meet its main goal in a late-stage trial.
Still, some analysts believe the drugmaker has plenty of potential left in its pipeline.Ultragenyx…